WO2010132474A3 - Stable elastomeric negative acoustic contrast particles and their use in acoustic radiation fields - Google Patents

Stable elastomeric negative acoustic contrast particles and their use in acoustic radiation fields Download PDF

Info

Publication number
WO2010132474A3
WO2010132474A3 PCT/US2010/034415 US2010034415W WO2010132474A3 WO 2010132474 A3 WO2010132474 A3 WO 2010132474A3 US 2010034415 W US2010034415 W US 2010034415W WO 2010132474 A3 WO2010132474 A3 WO 2010132474A3
Authority
WO
WIPO (PCT)
Prior art keywords
acoustic contrast
acoustic
contrast particles
negative acoustic
elastomeric negative
Prior art date
Application number
PCT/US2010/034415
Other languages
French (fr)
Other versions
WO2010132474A2 (en
Inventor
Gabriel Lopez
Gregory Kaduchak
Original Assignee
Stc.Unm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stc.Unm filed Critical Stc.Unm
Priority to US13/320,476 priority Critical patent/US9101664B2/en
Publication of WO2010132474A2 publication Critical patent/WO2010132474A2/en
Publication of WO2010132474A3 publication Critical patent/WO2010132474A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
    • C08L83/04—Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/225—Microparticles, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form

Abstract

We describe methods for synthesis and formulations of stable elastomeric negative acoustic contrast particles with controllable compressibility and density. These elastomeric negative acoustic contrast particles have a density/compressibility ratio that is less than that of water and therefore exhibit negative acoustic contrast under acoustic radiation exposure. This negative acoustic contrast allows our elastomeric negative acoustic contrast particles to be acoustically manipulated (e.g. separated) differently from other components (e.g. cells) within an aqueous solution. This disclosure also describes methods for biofunctionalization of the elastomeric negative acoustic contrast particles and as an example their use as platforms for bioassays. Potential applications of these elastomeric negative acoustic contrast particles include sensitive bioassays based on acoustic flow cytometry and other types of techniques that utilize acoustic fields, including ultrasound imaging and ultrasound triggered drug delivery.
PCT/US2010/034415 2009-05-11 2010-05-11 Stable elastomeric negative acoustic contrast particles and their use in acoustic radiation fields WO2010132474A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/320,476 US9101664B2 (en) 2009-05-11 2010-05-11 Stable elastomeric negative acoustic contrast particles and their use in acoustic radiation fields

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21602409P 2009-05-11 2009-05-11
US61/216,024 2009-05-11
US22796209P 2009-07-23 2009-07-23
US61/227,962 2009-07-23

Publications (2)

Publication Number Publication Date
WO2010132474A2 WO2010132474A2 (en) 2010-11-18
WO2010132474A3 true WO2010132474A3 (en) 2011-04-21

Family

ID=43085541

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2010/034411 WO2010132471A2 (en) 2009-05-11 2010-05-11 Synthesis of stable elastomeric negative acoustic contrast particles
PCT/US2010/034415 WO2010132474A2 (en) 2009-05-11 2010-05-11 Stable elastomeric negative acoustic contrast particles and their use in acoustic radiation fields

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2010/034411 WO2010132471A2 (en) 2009-05-11 2010-05-11 Synthesis of stable elastomeric negative acoustic contrast particles

Country Status (2)

Country Link
US (2) US8658734B2 (en)
WO (2) WO2010132471A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132471A2 (en) * 2009-05-11 2010-11-18 Stc.Unm Synthesis of stable elastomeric negative acoustic contrast particles
US9797897B2 (en) 2012-03-26 2017-10-24 Duke University Acoustically responsive particles
CA2984492A1 (en) 2015-04-29 2016-11-03 Flodesign Sonics, Inc. Acoustophoretic device for angled wave particle deflection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5147631A (en) * 1991-04-30 1992-09-15 Du Pont Merck Pharmaceutical Company Porous inorganic ultrasound contrast agents
US5487390A (en) * 1990-10-05 1996-01-30 Massachusetts Institute Of Technology Gas-filled polymeric microbubbles for ultrasound imaging
WO2006031299A2 (en) * 2004-07-29 2006-03-23 The Regents Of The University Of California Ultrasonic analyte concentration and application in flow cytometry
WO2008122051A1 (en) * 2007-04-02 2008-10-09 Acoustic Cytometry Systems, Inc. Methods and devices for enhanced analysis of field focused cells and particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395666A (en) 1993-01-08 1995-03-07 Lrc Products Ltd. Flexible elastomeric article with enhanced lubricity
US20060102871A1 (en) 2003-04-08 2006-05-18 Xingwu Wang Novel composition
US8083068B2 (en) 2007-04-09 2011-12-27 Los Alamos National Security, Llc Apparatus for separating particles utilizing engineered acoustic contrast capture particles
US7837040B2 (en) * 2007-04-09 2010-11-23 Los Alamos National Security, Llc Acoustic concentration of particles in fluid flow
WO2010132471A2 (en) * 2009-05-11 2010-11-18 Stc.Unm Synthesis of stable elastomeric negative acoustic contrast particles
JP5887275B2 (en) * 2009-12-04 2016-03-16 ライフ テクノロジーズ コーポレーション Apparatus, system, method and computer readable medium for acoustic flow cytometry
US20140147860A1 (en) * 2011-06-27 2014-05-29 Life Technologies Corporation Acoustic Cytometry Methods and Protocols

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487390A (en) * 1990-10-05 1996-01-30 Massachusetts Institute Of Technology Gas-filled polymeric microbubbles for ultrasound imaging
US5147631A (en) * 1991-04-30 1992-09-15 Du Pont Merck Pharmaceutical Company Porous inorganic ultrasound contrast agents
WO2006031299A2 (en) * 2004-07-29 2006-03-23 The Regents Of The University Of California Ultrasonic analyte concentration and application in flow cytometry
WO2008122051A1 (en) * 2007-04-02 2008-10-09 Acoustic Cytometry Systems, Inc. Methods and devices for enhanced analysis of field focused cells and particles

Also Published As

Publication number Publication date
WO2010132474A2 (en) 2010-11-18
US9101664B2 (en) 2015-08-11
US8658734B2 (en) 2014-02-25
WO2010132471A2 (en) 2010-11-18
WO2010132471A3 (en) 2011-04-21
US20120064639A1 (en) 2012-03-15
US20120065329A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
Della Torre et al. Accumulation and embryotoxicity of polystyrene nanoparticles at early stage of development of sea urchin embryos Paracentrotus lividus
Besseling et al. Nanoplastic affects growth of S. obliquus and reproduction of D. magna
Post et al. Occurrence and potential significance of perfluorooctanoic acid (PFOA) detected in New Jersey public drinking water systems
Pardo et al. Low cytotoxicity of inorganic nanotubes and fullerene-like nanostructures in human bronchial epithelial cells: relation to inflammatory gene induction and antioxidant response
EP3495022A3 (en) Vascular characteization using ultrasound imaging
EP4248740A3 (en) Humanized sirpa-il15 knockin mice and methods of use thereof
Midgett et al. In vitro evaluation of the effects of perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) on IL‐2 production in human T‐cells
Fellner et al. Toll-like receptor-4 inhibitor TAK-242 attenuates motor dysfunction and spinal cord pathology in an amyotrophic lateral sclerosis mouse model
EP4233537A3 (en) Humanized m-csf mice and uses thereof
WO2010025300A3 (en) Imaging based on cosmic-ray produced charged particles
TW200700608A (en) Fiber treatment agent, fiber treated with the fiber treatment agent, fiber fabric, laminate body and fiber treatment method
WO2006128167A3 (en) Optical coherence tomographic detection of cells and compositions
EA201101332A1 (en) COMPOSITIONS
CR9339A (en) PHARMACEUTICAL FORMS WITH IMPROVED PHARMACOCINETIC PROPERTIES
WO2008120998A3 (en) Acoustically sensitive drug delivery particles
WO2010132474A3 (en) Stable elastomeric negative acoustic contrast particles and their use in acoustic radiation fields
González-Vega et al. Lung models to evaluate silver nanoparticles’ toxicity and their impact on human health
PL2052273T3 (en) 13c-mr imaging or spectroscopy of cell death
Andreani et al. Ecotoxicity to freshwater organisms and cytotoxicity of nanomaterials: Are we generating sufficient data for their risk assessment?
Werrel et al. Use and benefit of a controlled-atmosphere cone calorimeter
Jankowska-Kieltyka et al. Metabolic response of RAW 264.7 macrophages to exposure to crude particulate matter and a reduced content of organic matter
Zhou et al. Bioactive Molecules against Rheumatoid Arthritis by Suppressing Pyroptosis
Chiang et al. Treatment of arsenite intoxication-induced peripheral vasculopathy with mesenchymal stem cells
Bernardini et al. Effects of hydrogen sulfide donor NaHS on porcine vascular wall-mesenchymal stem cells
Peng et al. Influence of lenvatinib on the functional reprogramming of peripheral myeloid cells in the context of non-medullary thyroid carcinoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10775418

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13320476

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10775418

Country of ref document: EP

Kind code of ref document: A2